Glaxo (NYSE:GSK) recently announced that it is initiating a phase III program consisting of two studies, namely COMBI-d and COMBI-v. The studies are aimed at evaluating the safety and efficacy of dabrafenib (2118436, BRaf inhibitor) and trametinib (1120212, MEK inhibitor) combination therapy in patients with BRaf mutation-positive metastatic cutaneous melanoma.
The COMBI-d phase III study will compare the combination of dabrafenib and trametinib with dabrafenib alone. The study will evaluate the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards